Loading...
12 spironolactone COVID-19 controlled studies, 3 RCTs
77% improvement
for early treatment, RR
0.23
[0.08-0.66]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani
77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI]
Treatment
Control
Cadegiani
83%
0.17 [0.06-0.51]
recov. time
8 (n)
262 (n)
Cadegiani
38%
0.62 [0.42-0.91]
viral time
8 (n)
262 (n)
Mareev (RCT)
11%
0.89 [0.65-1.22]
no recov.
33 (n)
33 (n)
CT1
Mareev (RCT)
39%
0.61 [0.14-0.97]
no recov.
14/24
20/21
CT1
Mareev (RCT)
8%
0.92 [0.77-1.09]
hosp. time
33 (n)
33 (n)
CT1
Mareev (RCT)
87%
0.13 [0.01-2.25]
viral+
0/17
3/13
CT1
Ersoy (ICU)
46%
0.54 [0.36-0.81]
death
14/30
26/30
ICU patients
Davarpanah
78%
0.22 [0.08-0.55]
hosp.
6/103
23/103
CT1
Davarpanah
64%
0.36 [0.21-0.60]
recov. time
103 (n)
103 (n)
CT1
Abbasi (SB RCT)
55%
0.45 [0.18-1.13]
death
5/51
19/87
Abbasi (SB RCT)
34%
0.66 [0.30-1.48]
ventilation
7/51
18/87
Abbasi (SB RCT)
19%
0.81 [0.42-1.59]
ICU
10/51
21/87
Abbasi (SB RCT)
47%
0.53 [0.39-0.72]
no recov.
51 (n)
87 (n)
Wadhwa (RCT)
72%
0.28 [0.09-0.85]
progression
4/74
9/46
Wadhwa (RCT)
49%
0.51 [0.27-0.95]
no disch.
13/74
16/46
Wadhwa (RCT)
18%
0.82 [0.67-1.00]
recov. time
74 (n)
46 (n)
Mehrizi
32%
0.68 [0.65-0.72]
death
population-based cohort
Holt
-129%
2.29 [1.59-3.32]
death/ICU
16/31
148/658
Jeon
77%
0.23 [0.08-0.64]
cases
case control
MacFadden
7%
0.93 [0.88-0.98]
cases
n/a
n/a
Cousins (PSM)
81%
0.19 [0.06-0.65]
ventilation
731 (n)
731 (n)
Cousins (PSM)
66%
0.34 [0.17-0.68]
ICU
731 (n)
731 (n)
Cousins (PSM)
18%
0.82 [0.71-0.93]
death
390/12,504
479/12,504
Cousins (PSM)
12%
0.88 [0.79-0.99]
death
521/16,324
592/16,324
Cousins (PSM)
15%
0.85 [0.77-0.94]
death
671/20,690
783/20,690
Cousins (PSM)
17%
0.83 [0.77-0.91]
ventilation
936/12,504
1,118/12,504
Cousins (PSM)
17%
0.83 [0.77-0.89]
ventilation
1,212/16,324
1,459/16,324
Cousins (PSM)
10%
0.90 [0.84-0.95]
ventilation
1,524/20,690
1,701/20,690
Spironolactone COVID-19 outcomes
c19 early .org
March 2024
1 CT: study uses combined treatment
Favors spironolactone
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit